Disseminated Intravascular Coagulation vs Heparin-Induced Thrombocytopenia

Why Disseminated intravascular coagulation is correct

• This patient has disseminated intravascular coagulation (DIC).
• The core concept is systemic activation of the coagulation cascade that consumes platelets and clotting factors while simultaneously activating fibrinolysis, producing both bleeding and microthrombosis.
• Sepsis, especially gram-negative endotoxemia, is among the most common triggers (others include trauma, malignancy, and obstetric catastrophes).
• The combination of thrombocytopenia, prolonged PT and aPTT, LOW fibrinogen, high D-dimer, and schistocytes is the classic laboratory signature.

Why the others are wrong

• Immune thrombocytopenic purpura — isolated thrombocytopenia with NORMAL PT/aPTT and normal fibrinogen; it does not cause consumptive coagulopathy or schistocytes.
• Thrombotic thrombocytopenic purpura — a microangiopathy with thrombocytopenia and schistocytes, but coagulation times and fibrinogen are typically NORMAL, and it features neurologic changes and renal injury rather than consumption of clotting factors.
• Vitamin K deficiency coagulopathy — prolongs PT (then aPTT) by reducing factors II, VII, IX, X, but platelets, fibrinogen, and D-dimer are normal and there are no schistocytes.

The consumptive profile with low fibrinogen and high D-dimer in sepsis makes DIC the answer.

Why Use of unfractionated heparin is correct

• Heparin-induced thrombocytopenia is driven by antibodies to platelet factor 4-heparin complexes, and unfractionated heparin binds PF4 far more avidly than other agents, giving it the highest HIT risk.
• The post-cardiac-surgery setting compounds risk, as bypass exposes patients to high-dose UFH and the highest PF4 antibody seroconversion rates.
• A 50% platelet drop at day 5 with new limb thrombosis is the classic timing and thrombotic phenotype of HIT.

Why the others are wrong

• Use of low-molecular-weight heparin — Right-drug-class wrong-magnitude trap: LMWH can cause HIT but at roughly one-tenth the rate of UFH, so it is not the strongest risk factor.
• Use of fondaparinux for prophylaxis — Buzzword-reversal trap: fondaparinux essentially does not form immunogenic PF4 complexes and is actually used to treat HIT, not cause it.
• Use of warfarin for prophylaxis — Anchoring trap: warfarin causes no PF4 immune reaction, and starting it during acute HIT risks warfarin-induced limb gangrene.